| Authors: |
Hamilton E; Breast Cancer Research Program, Sarah Cannon Research Institute, Nashville, TN, USA. erika.hamilton@scri.com.; Sarah Cannon Research Institute, 335 24th Avenue North, Suite 300, Nashville, TN, 37203, USA. erika.hamilton@scri.com., Pluard T; Koontz Center for Advanced Breast Cancer, Saint Luke's Cancer Institute, Kansas City, MO, USA., Wang JS; Hematology and Oncology, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, USA., Morikawa A; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA., Johnston S; Breast Unit, Royal Marsden NHS Foundation Trust, London, UK., Dees EC; Department of Medicine, Division of Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA., Vaklavas C; Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Armstrong A; Division of Cancer Studies, University of Manchester, Manchester, UK.; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK., Munster P; Division of Hematology and Oncology, University of California, San Francisco, CA, USA., Unni N; Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA., Wright GS; Medical Oncology, Florida Cancer Specialists & Research Institute/Sarah Cannon Research Institute, Trinity, FL, USA., Kayali F; Hematology and Oncology, Florida Cancer Specialists, Lakewood Ranch/Sarasota, FL, USA., Song T; Eisai Inc, Nutley, NJ, USA., Rong Y; Eisai Inc, Nutley, NJ, USA., Yamaguchi K; Eisai Co., Ltd, Tokyo, Japan., Juric D; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. |
